Figure 3 | Scientific Reports

Figure 3

From: First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis

Figure 3

Therapeutic efficacy of topical omilancor treatment in IL-23-induced model of mouse PsO in dorsal skin. WT mice were shaved and daily challenged with intradermal injection of IL-23 at dorsal skin. Vehicle or omilancor formulations were administered daily 1 h post IL-23 injection. Mice were euthanized at day 4. Representative photomicrographs of H&E-stained dorsal skin at day 4 (A). Epidermal hyperplasia (|-|) and hyperkeratosis (*) are represented. Percentage of IFNγ+  CD4+ T cells (B), TNFα+ CD4+ T cells (C), Th17 cells (D) and Tfh cells (E) was quantified in draining ILNs through flow cytometry analysis. Ccl20 (F), Cxcl1 (G), and IL10 (H) expression from dorsal skin was measured by qRT-PCR. Percentage of Pan cytokeratine+ Ki67+ cells (I) was assessed through flow cytometry analysis. *P ≤ 0.05.

Back to article page